Review
. 2015 May; 45(7):1892-905.
doi: 10.1002/eji.201344413.

Inhibitory receptors as targets for cancer immunotherapy

Meghan E Turnis 1 Lawrence P Andrews 2 Dario A A Vignali 1 
Affiliations
  • PMID: 26018646
  •     138 References
  •     53 citations

Abstract

Inhibitory receptors expressed on T cells control immune responses while limiting autoimmunity. However, tumors can hijack these "checkpoints" for protection from immune attack. Tumor-specific T cells that exhibit an exhausted, unresponsive phenotype express high levels of inhibitory receptors including CTLA4, PD1, and LAG3, among others. Intratumoral regulatory T cells promote immunosuppression and also express multiple inhibitory receptors. Overcoming this inhibitory receptor-mediated immune tolerance has thus been a major focus of recent cancer immunotherapeutic developments. Here, we review how boosting the host's immune system by blocking inhibitory receptor signaling with antagonistic mAbs restores the capacity of T cells to drive durable antitumor immune responses. Clinical trials targeting the CTLA4 and PD1 pathways have shown durable effects in multiple tumor types. Many combinatorial therapies are currently being investigated with encouraging results that highlight enhanced antitumor immunogenicity and improved patient survival. Finally, we will discuss the ongoing identification and dissection of novel T-cell inhibitory receptor pathways, which could lead to the development of new combinatorial therapeutic approaches.

Keywords: CTLA4; Cancer immunotherapy; Inhibitory receptors; LAG3; PD1.

Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice.
Marcio O Lasaro, Marina Sazanovich, +8 authors, Hildegund Cj Ertl.
Mol Ther, 2011 May 19; 19(9). PMID: 21587210    Free PMC article.
Reversal of the TCR stop signal by CTLA-4.
Helga Schneider, Jos Downey, +7 authors, Christopher E Rudd.
Science, 2006 Aug 26; 313(5795). PMID: 16931720
Highly Cited.
Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer.
Jingting Jiang, Yibei Zhu, +7 authors, Xueguang Zhang.
Cancer Immunol Immunother, 2010 Aug 21; 59(11). PMID: 20725832
Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal.
Yuning Lu, Helga Schneider, Christopher E Rudd.
Blood, 2012 Oct 11; 120(23). PMID: 23047820    Free PMC article.
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Guifang Cai, Anukanth Anumanthan, +3 authors, Gordon J Freeman.
Nat Immunol, 2008 Jan 15; 9(2). PMID: 18193050
Highly Cited.
B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response.
Dagmar Quandt, Eckhard Fiedler, +2 authors, Barbara Seliger.
Clin Cancer Res, 2011 Mar 08; 17(10). PMID: 21378130
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
Dung T Le, Eric Lutz, +8 authors, Daniel A Laheru.
J Immunother, 2013 Aug 09; 36(7). PMID: 23924790    Free PMC article.
Highly Cited.
Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells.
J Kraan, P van den Broek, +4 authors, S Sleijfer.
Br J Cancer, 2014 Jun 04; 111(1). PMID: 24892449    Free PMC article.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Qing Zhou, Meghan E Munger, +8 authors, Bruce R Blazar.
Blood, 2011 Mar 10; 117(17). PMID: 21385853    Free PMC article.
Highly Cited.
The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation.
Yinghua Xu, Nicholas H Hunt, Shisan Bao.
Cell Res, 2008 Nov 26; 18(12). PMID: 19030026
Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.
Gavin J Wright, Holly Cherwinski, +12 authors, A Neil Barclay.
J Immunol, 2003 Sep 10; 171(6). PMID: 12960329
Highly Cited.
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation.
Yasushi Onishi, Zoltan Fehervari, Tomoyuki Yamaguchi, Shimon Sakaguchi.
Proc Natl Acad Sci U S A, 2008 Jul 19; 105(29). PMID: 18635688    Free PMC article.
Highly Cited.
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.
Shawn D Blackburn, Haina Shin, +7 authors, E John Wherry.
Nat Immunol, 2008 Dec 02; 10(1). PMID: 19043418    Free PMC article.
Highly Cited.
Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells.
Brian T Kawasaki, Tashan Mistree, +2 authors, William L Farrar.
Biochem Biophys Res Commun, 2007 Oct 30; 364(4). PMID: 17964286    Free PMC article.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.
Andrew J S Furness, Frederick Arce Vargas, Karl S Peggs, Sergio A Quezada.
Trends Immunol, 2014 Jun 24; 35(7). PMID: 24953012
Review.
Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.
Tibor Keler, Ed Halk, +8 authors, Alan Korman.
J Immunol, 2003 Nov 25; 171(11). PMID: 14634142
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, +21 authors, Axel Hauschild.
J Clin Oncol, 2013 Jan 09; 31(5). PMID: 23295794    Free PMC article.
Highly Cited.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.
G Dranoff, A D Crawford, +7 authors, J A Whitsett.
Science, 1994 Apr 29; 264(5159). PMID: 8171324
Highly Cited.
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity.
Gabriel L Sica, In Hak Choi, +7 authors, Lieping Chen.
Immunity, 2003 Jun 24; 18(6). PMID: 12818165
Highly Cited.
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Amy E Moran, Magdalena Kovacsovics-Bankowski, Andrew D Weinberg.
Curr Opin Immunol, 2013 Feb 19; 25(2). PMID: 23414607    Free PMC article.
Review.
Down-regulation of the macrophage lineage through interaction with OX2 (CD200).
R M Hoek, S R Ruuls, +9 authors, J D Sedgwick.
Science, 2000 Dec 02; 290(5497). PMID: 11099416
Highly Cited.
The TIGIT/CD226 axis regulates human T cell function.
Ester Lozano, Margarita Dominguez-Villar, Vijay Kuchroo, David A Hafler.
J Immunol, 2012 Mar 20; 188(8). PMID: 22427644    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
K Abiko, N Matsumura, +7 authors, M Mandai.
Br J Cancer, 2015 Apr 14; 112(9). PMID: 25867264    Free PMC article.
Highly Cited.
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F Stephen Hodi, Sandra Lee, +7 authors, John M Kirkwood.
JAMA, 2014 Nov 05; 312(17). PMID: 25369488    Free PMC article.
Highly Cited.
PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
Expression of programmed death 1 ligands by murine T cells and APC.
Tomohide Yamazaki, Hisaya Akiba, +9 authors, Hideo Yagita.
J Immunol, 2002 Nov 08; 169(10). PMID: 12421930
Highly Cited.
Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation.
Gautam Adhikary, Dan Grun, +9 authors, Richard L Eckert.
PLoS One, 2014 Jan 01; 8(12). PMID: 24376802    Free PMC article.
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, +3 authors, Nagahiro Minato.
Proc Natl Acad Sci U S A, 2002 Sep 10; 99(19). PMID: 12218188    Free PMC article.
Highly Cited.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
B7-H5 costimulates human T cells via CD28H.
Yuwen Zhu, Sheng Yao, +13 authors, Lieping Chen.
Nat Commun, 2013 Jun 21; 4. PMID: 23784006    Free PMC article.
The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival.
Changjun He, Haiquan Qiao, Hongchi Jiang, Xueying Sun.
Clin Dev Immunol, 2011 Oct 21; 2011. PMID: 22013483    Free PMC article.
Review.
LAG-3 regulates plasmacytoid dendritic cell homeostasis.
Creg J Workman, Yao Wang, +4 authors, Dario A A Vignali.
J Immunol, 2009 Feb 10; 182(4). PMID: 19201841    Free PMC article.
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
S Muenst, A R Schaerli, +9 authors, S D Soysal.
Breast Cancer Res Treat, 2014 May 21; 146(1). PMID: 24842267    Free PMC article.
Highly Cited.
Role of LAG-3 in regulatory T cells.
Ching-Tai Huang, Creg J Workman, +11 authors, Dario A A Vignali.
Immunity, 2004 Oct 16; 21(4). PMID: 15485628
Highly Cited.
Cancer classification using the Immunoscore: a worldwide task force.
Jérôme Galon, Franck Pagès, +61 authors, Bernard A Fox.
J Transl Med, 2012 Oct 05; 10. PMID: 23034130    Free PMC article.
Highly Cited. Review.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, +8 authors, Hassane M Zarour.
J Clin Invest, 2015 Apr 14; 125(5). PMID: 25866972    Free PMC article.
Highly Cited.
Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.
Noa Stanietsky, Tihana Lenac Rovis, +6 authors, Ofer Mandelboim.
Eur J Immunol, 2013 May 17; 43(8). PMID: 23677581    Free PMC article.
B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation.
Carsten Krieg, Onur Boyman, Yang-Xin Fu, Jonathan Kaye.
Nat Immunol, 2007 Jan 09; 8(2). PMID: 17206146
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.
Xin Yu, Kristin Harden, +9 authors, Jane L Grogan.
Nat Immunol, 2008 Nov 18; 10(1). PMID: 19011627
Highly Cited.
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, +18 authors, F Stephen Hodi.
J Clin Oncol, 2014 Mar 05; 32(10). PMID: 24590637    Free PMC article.
Highly Cited.
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
Nicole Joller, Ester Lozano, +13 authors, Vijay K Kuchroo.
Immunity, 2014 Apr 22; 40(4). PMID: 24745333    Free PMC article.
Highly Cited.
Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Denarda Dangaj, Evripidis Lanitis, +7 authors, Nathalie Scholler.
Cancer Res, 2013 Jun 01; 73(15). PMID: 23722540    Free PMC article.
VISTA is an immune checkpoint molecule for human T cells.
J Louise Lines, Eirini Pantazi, +8 authors, Randolph Noelle.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691993    Free PMC article.
Highly Cited.
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
Alena Gros, Paul F Robbins, +13 authors, Steven A Rosenberg.
J Clin Invest, 2014 Mar 29; 124(5). PMID: 24667641    Free PMC article.
Highly Cited.
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.
Zhi-Zhang Yang, Deanna M Grote, +5 authors, Stephen M Ansell.
J Clin Invest, 2012 Mar 20; 122(4). PMID: 22426209    Free PMC article.
Highly Cited.
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Li Wang, Rotem Rubinstein, +10 authors, Randolph J Noelle.
J Exp Med, 2011 Mar 09; 208(3). PMID: 21383057    Free PMC article.
Highly Cited.
Tim-3: an emerging target in the cancer immunotherapy landscape.
Ana C Anderson.
Cancer Immunol Res, 2014 May 06; 2(5). PMID: 24795351
Highly Cited. Review.
Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression.
Cecilia Oderup, Lukas Cederbom, +2 authors, Fredrik Ivars.
Immunology, 2006 Jun 15; 118(2). PMID: 16771859    Free PMC article.
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
Giuseppina Della Vittoria Scarpati, Celeste Fusciello, +4 authors, Stefano Pepe.
Onco Targets Ther, 2014 Feb 27; 7. PMID: 24570590    Free PMC article.
Review.
Dendritic-cell-based therapeutic cancer vaccines.
Karolina Palucka, Jacques Banchereau.
Immunity, 2013 Jul 31; 39(1). PMID: 23890062    Free PMC article.
Highly Cited. Review.
Breakthrough of the year 2013. Cancer immunotherapy.
Jennifer Couzin-Frankel.
Science, 2013 Dec 21; 342(6165). PMID: 24357284
Highly Cited.
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Dmitriy Zamarin, Rikke B Holmgaard, +6 authors, James P Allison.
Sci Transl Med, 2014 Mar 07; 6(226). PMID: 24598590    Free PMC article.
Highly Cited.
Immune checkpoint inhibitors in NSCLC.
Douglas B Johnson, Matthew J Rioth, Leora Horn.
Curr Treat Options Oncol, 2014 Aug 07; 15(4). PMID: 25096781    Free PMC article.
Review.
Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223).
Nianyu Li, Creg J Workman, Stefani M Martin, Dario A A Vignali.
J Immunol, 2004 Nov 24; 173(11). PMID: 15557174
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Sandip Pravin Patel, Razelle Kurzrock.
Mol Cancer Ther, 2015 Feb 20; 14(4). PMID: 25695955
Highly Cited. Review.
Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
E John Wherry, Sang-Jun Ha, +7 authors, Rafi Ahmed.
Immunity, 2007 Oct 24; 27(4). PMID: 17950003
Highly Cited.
B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma.
Lu-jun Chen, Jing Sun, +6 authors, Xue-guang Zhang.
Cancer Immunol Immunother, 2011 Apr 27; 60(7). PMID: 21519829
Pembrolizumab: first global approval.
Raewyn M Poole.
Drugs, 2014 Oct 22; 74(16). PMID: 25331768
Review.
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.
Brian A Baldo.
Oncoimmunology, 2013 Nov 20; 2(10). PMID: 24251081    Free PMC article.
Review.
Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer.
Jing Sun, Yong Mao, +4 authors, Xue-Guang Zhang.
Oncol Lett, 2013 Nov 02; 6(5). PMID: 24179504    Free PMC article.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, +18 authors, Weiping Zou.
Nat Med, 2004 Aug 24; 10(9). PMID: 15322536
Highly Cited.
Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.
Reginald M Gorczynski, Zhiqi Chen, +2 authors, Kai Yu.
Breast Cancer Res Treat, 2013 Oct 30; 142(2). PMID: 24166280    Free PMC article.
B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients.
Wenting Liu, Kiyosumi Shibata, +4 authors, Fumitaka Kikkawa.
Mol Clin Oncol, 2014 Mar 22; 2(2). PMID: 24649336    Free PMC article.
B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Willemijn Hobo, Wieger J Norde, +8 authors, Harry Dolstra.
J Immunol, 2012 May 29; 189(1). PMID: 22634623
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.
Christian J Maine, Nor Haslinda Abdul Aziz, +5 authors, Sadaf Ghaem-Maghami.
Cancer Immunol Immunother, 2013 Dec 04; 63(3). PMID: 24297569
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.
Maria Vela, Mariana Aris, +2 authors, Leonor Kremer.
Front Immunol, 2015 Feb 18; 6. PMID: 25688243    Free PMC article.
Highly Cited. Review.
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Julien Fourcade, Zhaojun Sun, +6 authors, Hassane M Zarour.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819923    Free PMC article.
Highly Cited.
Co-inhibitory pathways and their importance in immune regulation.
Naoka Murakami, Leonardo V Riella.
Transplantation, 2014 Jul 01; 98(1). PMID: 24978034
Review.
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.
Kim Kramer, Brian H Kushner, +9 authors, Nai-Kong V Cheung.
J Neurooncol, 2009 Nov 06; 97(3). PMID: 19890606    Free PMC article.
Metalloproteases regulate T-cell proliferation and effector function via LAG-3.
Nianyu Li, Yao Wang, +10 authors, Dario A A Vignali.
EMBO J, 2007 Jan 25; 26(2). PMID: 17245433    Free PMC article.
Mechanisms of foxp3+ T regulatory cell-mediated suppression.
Ethan M Shevach.
Immunity, 2009 May 26; 30(5). PMID: 19464986
Highly Cited. Review.
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Benjamin Boyerinas, Caroline Jochems, +4 authors, Jeffrey Schlom.
Cancer Immunol Res, 2015 May 28; 3(10). PMID: 26014098    Free PMC article.
Highly Cited.
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Laurent Derré, Jean-Paul Rivals, +6 authors, Daniel E Speiser.
J Clin Invest, 2009 Dec 30; 120(1). PMID: 20038811    Free PMC article.
Highly Cited.
Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.
Anne-Sophie Gautron, Margarita Dominguez-Villar, Marine de Marcken, David A Hafler.
Eur J Immunol, 2014 May 20; 44(9). PMID: 24838857    Free PMC article.
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
Michael Kalos, Carl H June.
Immunity, 2013 Jul 31; 39(1). PMID: 23890063    Free PMC article.
Highly Cited. Review.
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor.
Y Morel, J M Schiano de Colella, +9 authors, R T Costello.
J Immunol, 2000 Oct 18; 165(8). PMID: 11035077
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Jérôme Galon, Helen K Angell, Davide Bedognetti, Francesco M Marincola.
Immunity, 2013 Jul 31; 39(1). PMID: 23890060
Highly Cited. Review.
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.
Jens M Chemnitz, Richard V Parry, +2 authors, James L Riley.
J Immunol, 2004 Jul 09; 173(2). PMID: 15240681
Highly Cited.
CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria.
M J Barnes, T Griseri, +3 authors, A Izcue.
Mucosal Immunol, 2012 Aug 23; 6(2). PMID: 22910217    Free PMC article.
Treatment with ipilimumab: a case report of complete response in a metastatic malignant melanoma patient.
Alfredo Addeo, Ciro Roberto Rinaldi.
Case Rep Oncol, 2013 Jul 31; 6(2). PMID: 23898270    Free PMC article.
CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders.
Vinodh Pillai, Olga Pozdnyakova, +3 authors, David M Dorfman.
Am J Clin Pathol, 2013 Sep 21; 140(4). PMID: 24045551
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, +9 authors, Shingo Fujii.
Proc Natl Acad Sci U S A, 2007 Mar 16; 104(9). PMID: 17360651    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.
Shigeki Chiba, Muhammad Baghdadi, +12 authors, Masahisa Jinushi.
Nat Immunol, 2012 Jul 31; 13(9). PMID: 22842346    Free PMC article.
Highly Cited.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, +18 authors, Dario A A Vignali.
Cancer Res, 2011 Dec 22; 72(4). PMID: 22186141    Free PMC article.
Highly Cited.
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Ryosuke Hino, Kenji Kabashima, +5 authors, Yoshiki Tokura.
Cancer, 2010 Feb 10; 116(7). PMID: 20143437
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.
B Huard, P Gaulard, +2 authors, F Triebel.
Immunogenetics, 1994 Jan 01; 39(3). PMID: 7506235
Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo.
Creg J Workman, Linda S Cauley, +3 authors, Dario A A Vignali.
J Immunol, 2004 Apr 22; 172(9). PMID: 15100286
The role of B7 family molecules in hematologic malignancy.
Paul Greaves, John G Gribben.
Blood, 2012 Dec 12; 121(5). PMID: 23223433    Free PMC article.
Review.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
Julien Fourcade, Zhaojun Sun, +7 authors, Hassane M Zarour.
Cancer Res, 2011 Dec 30; 72(4). PMID: 22205715    Free PMC article.
Highly Cited.
Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.
Nicole Joller, Jason P Hafler, +5 authors, Vijay K Kuchroo.
J Immunol, 2011 Jan 05; 186(3). PMID: 21199897    Free PMC article.
Highly Cited.
VISTA Regulates the Development of Protective Antitumor Immunity.
Isabelle Le Mercier, Wenna Chen, +5 authors, Li Wang.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691994    Free PMC article.
Highly Cited.
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
W W Overwijk, A Tsung, +8 authors, N P Restifo.
J Exp Med, 1998 Jul 22; 188(2). PMID: 9670040    Free PMC article.
Highly Cited.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Thomas Powles, Joseph Paul Eder, +12 authors, Nicholas J Vogelzang.
Nature, 2014 Nov 28; 515(7528). PMID: 25428503
Highly Cited.
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Rikke B Holmgaard, Dmitriy Zamarin, +2 authors, James P Allison.
J Exp Med, 2013 Jun 12; 210(7). PMID: 23752227    Free PMC article.
Highly Cited.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, +20 authors, KEYNOTE-006 investigators.
N Engl J Med, 2015 Apr 22; 372(26). PMID: 25891173
Highly Cited.
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Alfons J M van den Eertwegh, Jurjen Versluis, +15 authors, Winald R Gerritsen.
Lancet Oncol, 2012 Feb 14; 13(5). PMID: 22326922
Highly Cited.
B7-H3-mediated tumor immunology: Friend or foe?
Ling Wang, Fu-Biao Kang, Bao-En Shan.
Int J Cancer, 2013 Sep 10; 134(12). PMID: 24013874
Review.
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.
Laurent Monney, Catherine A Sabatos, +9 authors, Vijay K Kuchroo.
Nature, 2002 Feb 02; 415(6871). PMID: 11823861
Highly Cited.
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.
S J Coles, E C Y Wang, +4 authors, R L Darley.
Leukemia, 2011 Jan 29; 25(5). PMID: 21274000    Free PMC article.
Melanoma drug wins US approval.
Heidi Ledford.
Nature, 2011 Apr 02; 471(7340). PMID: 21455150
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J Johnston, Laetitia Comps-Agrar, +9 authors, Jane L Grogan.
Cancer Cell, 2014 Dec 04; 26(6). PMID: 25465800
Highly Cited.
Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3.
Creg J Workman, Kari J Dugger, Dario A A Vignali.
J Immunol, 2002 Nov 08; 169(10). PMID: 12421911
TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Xin Gao, Yibei Zhu, +7 authors, Binfeng Lu.
PLoS One, 2012 Mar 01; 7(2). PMID: 22363469    Free PMC article.
Highly Cited.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, +3 authors, Ana C Anderson.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819927    Free PMC article.
Highly Cited.
Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Johnny Kao, Eric C Ko, +3 authors, Shu-Hsia Chen.
Crit Rev Oncol Hematol, 2010 Mar 23; 77(1). PMID: 20304669    Free PMC article.
Review.
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.
Lukas Baitsch, Amandine Legat, +11 authors, Daniel E Speiser.
PLoS One, 2012 Feb 22; 7(2). PMID: 22347406    Free PMC article.
Highly Cited.
Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
Ines Pires da Silva, Anne Gallois, +5 authors, Nina Bhardwaj.
Cancer Immunol Res, 2014 May 06; 2(5). PMID: 24795354    Free PMC article.
Highly Cited.
FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation.
David A Mancardi, Bruno Iannascoli, +3 authors, Pierre Bruhns.
J Clin Invest, 2008 Oct 25; 118(11). PMID: 18949059    Free PMC article.
Differential and tumor-specific expression of CD160 in B-cell malignancies.
Timothy W Farren, Jerome Giustiniani, +11 authors, Samir G Agrawal.
Blood, 2011 Jul 01; 118(8). PMID: 21715317    Free PMC article.
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Junko Matsuzaki, Sacha Gnjatic, +9 authors, Kunle Odunsi.
Proc Natl Acad Sci U S A, 2010 Apr 14; 107(17). PMID: 20385810    Free PMC article.
Highly Cited.
CD200R signaling in tumor tolerance and inflammation: A tricky balance.
Tomasz P Rygiel, Linde Meyaard.
Curr Opin Immunol, 2012 Jan 24; 24(2). PMID: 22264927
Review.
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.
Omar S Qureshi, Yong Zheng, +12 authors, David M Sansom.
Science, 2011 Apr 09; 332(6029). PMID: 21474713    Free PMC article.
Highly Cited.
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.
Volker Schirrmacher, Philippe Fournier.
Methods Mol Biol, 2009 Jul 02; 542. PMID: 19565923    Free PMC article.
Review.
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Deryk Loo, Ralph F Alderson, +21 authors, Paul A Moore.
Clin Cancer Res, 2012 May 23; 18(14). PMID: 22615450
Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223).
Creg J Workman, Dario A A Vignali.
J Immunol, 2005 Jan 07; 174(2). PMID: 15634887
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Omid Hamid, Henrik Schmidt, +9 authors, David Berman.
J Transl Med, 2011 Nov 30; 9. PMID: 22123319    Free PMC article.
Highly Cited.
High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
Hasni M'Hidi, Marie-Laure Thibult, +5 authors, Luc Xerri.
Am J Clin Pathol, 2009 Sep 19; 132(4). PMID: 19762537
Corrigendum: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
Yu-Hwa Huang, Chen Zhu, +21 authors, Richard S Blumberg.
Nature, 2016 Mar 17; 536(7616). PMID: 26982724    Free PMC article.
Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.
Masaaki Hashiguchi, Hiroko Kobori, +3 authors, Miyuki Azuma.
Proc Natl Acad Sci U S A, 2008 Jul 25; 105(30). PMID: 18650384    Free PMC article.
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Christine Pasero, Daniel E Speiser, Laurent Derré, Daniel Olive.
Curr Opin Pharmacol, 2012 Mar 27; 12(4). PMID: 22445654
Review.
Increase of circulating B7-H4-expressing CD68+ macrophage correlated with clinical stage of lung carcinomas.
Cheng Chen, Yi-Bei Zhu, +3 authors, Jian-An Huang.
J Immunother, 2012 Apr 13; 35(4). PMID: 22495393
Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).
Creg J Workman, Dennis S Rice, +2 authors, Dario A A Vignali.
Eur J Immunol, 2002 Sep 05; 32(8). PMID: 12209638
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, +16 authors, Philippe Armand.
N Engl J Med, 2014 Dec 09; 372(4). PMID: 25482239    Free PMC article.
Highly Cited.
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
Ilona Kryczek, Linhua Zou, +12 authors, Weiping Zou.
J Exp Med, 2006 Apr 12; 203(4). PMID: 16606666    Free PMC article.
Highly Cited.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Genetic and Epigenetic Regulation of PD-1 Expression.
Alexander P R Bally, James W Austin, Jeremy M Boss.
J Immunol, 2016 Mar 06; 196(6). PMID: 26945088    Free PMC article.
Review.
Emerging Opportunities and Challenges in Cancer Immunotherapy.
Theresa L Whiteside, Sandra Demaria, +2 authors, Ignacio Melero.
Clin Cancer Res, 2016 Apr 17; 22(8). PMID: 27084738    Free PMC article.
Highly Cited. Review.
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.
Noha Abdel-Wahab, Mohsin Shah, Maria E Suarez-Almazor.
PLoS One, 2016 Jul 30; 11(7). PMID: 27472273    Free PMC article.
Highly Cited. Systematic Review.
Harnessing the immune system to improve cancer therapy.
Nikos E Papaioannou, Ourania V Beniata, +2 authors, Pinelopi Samara.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563648    Free PMC article.
Highly Cited. Review.
Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement.
Pauline Gravelle, Catherine Do, +13 authors, Camille Laurent.
Oncoimmunology, 2016 Dec 19; 5(10). PMID: 27990323    Free PMC article.
LAG3 (CD223) as a cancer immunotherapy target.
Lawrence P Andrews, Ariel E Marciscano, Charles G Drake, Dario A A Vignali.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258692    Free PMC article.
Highly Cited. Review.
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Pauline Gravelle, Barbara Burroni, +7 authors, Camille Laurent.
Oncotarget, 2017 Apr 14; 8(27). PMID: 28402953    Free PMC article.
Review.
Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis.
Kerstin Strömvall, Elin Thysell, Sofia Halin Bergström, Anders Bergh.
PLoS One, 2017 May 05; 12(5). PMID: 28472073    Free PMC article.
Industry 'road tests' new wave of immune checkpoints.
Ken Garber.
Nat Biotechnol, 2017 Jun 08; 35(6). PMID: 28591107
Signals that drive T follicular helper cell formation.
Louise M C Webb, Michelle A Linterman.
Immunology, 2017 Jun 20; 152(2). PMID: 28628194    Free PMC article.
Review.
Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.
Mahboubeh Yazdanifar, Ru Zhou, Pinku Mukherjee.
Curr Trends Immunol, 2016 Jan 01; 17. PMID: 28659689    Free PMC article.
Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth.
Kerstin Strömvall, Marie Lundholm, +2 authors, Sofia Halin Bergström.
PLoS One, 2017 Oct 27; 12(10). PMID: 29073272    Free PMC article.
Downregulated IL-21 Response and T Follicular Helper Cell Exhaustion Correlate with Compromised CD8 T Cell Immunity during Chronic Toxoplasmosis.
Magali M Moretto, SuJin Hwang, Imtiaz A Khan.
Front Immunol, 2017 Nov 23; 8. PMID: 29163509    Free PMC article.
Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer.
Yunxuan Wang, Tieying Dong, +3 authors, Qingyuan Zhang.
J Breast Cancer, 2018 Jul 03; 21(2). PMID: 29963107    Free PMC article.
Bilateral anterior uveitis after immunotherapy for malignant melanoma.
Chia-Jui Chang, Shih-Jen Chen, De-Kuang Hwang, Catherine Jui-Ling Liu.
Taiwan J Ophthalmol, 2018 Oct 09; 8(3). PMID: 30294532    Free PMC article.
Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells.
Suresh Pallikkuth, Rajendra Pahwa, +9 authors, Savita Pahwa.
PLoS One, 2018 Nov 01; 13(10). PMID: 30379878    Free PMC article.
Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes.
Ines de Santiago, Christopher Yau, +5 authors, Shivan Sivakumar.
Int J Cancer, 2019 Feb 06; 145(4). PMID: 30720864    Free PMC article.
The Pathogenesis of Sepsis and Potential Therapeutic Targets.
Min Huang, Shaoli Cai, Jingqian Su.
Int J Mol Sci, 2019 Nov 02; 20(21). PMID: 31671729    Free PMC article.
Review.
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.
Xinjie Xu, Qihang Sun, +8 authors, Yuhua Li.
Front Immunol, 2019 Dec 05; 10. PMID: 31798590    Free PMC article.
Review.
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Elisa Ruffo, Richard C Wu, +2 authors, Dario A A Vignali.
Semin Immunol, 2019 Oct 13; 42. PMID: 31604537    Free PMC article.
Review.
CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
January Salas-Mckee, Weimin Kong, +4 authors, Joseph A Fraietta.
Hum Vaccin Immunother, 2019 Feb 09; 15(5). PMID: 30735463    Free PMC article.
The role of the innate immune system in the development and treatment of hepatocellular carcinoma.
Christoph Roderburg, Alexander Wree, +2 authors, Frank Tacke.
Hepat Oncol, 2020 Apr 11; 7(1). PMID: 32273975    Free PMC article.
Review.
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma.
Niklas Klümper, Damian J Ralser, +8 authors, Dimo Dietrich.
J Immunother Cancer, 2020 Apr 03; 8(1). PMID: 32234847    Free PMC article.
Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy.
Xiaojie Yu, Xiao Huang, +6 authors, Lijun Zhou.
MAbs, 2019 Jun 27; 11(6). PMID: 31242068    Free PMC article.
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.
Carlo Gabriele Tocchetti, Christian Cadeddu, +12 authors, Giuseppe Mercuro.
Antioxid Redox Signal, 2017 Apr 12; 30(18). PMID: 28398124    Free PMC article.
Review.
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses.
Wenjie Zhai, Xiuman Zhou, +6 authors, Yanfeng Gao.
Acta Pharm Sin B, 2020 Jul 10; 10(6). PMID: 32642411    Free PMC article.
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors.
Lingli Yan, Bainan Liu.
Onco Targets Ther, 2019 Jan 15; 12. PMID: 30636882    Free PMC article.
Review.
Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.
Ravneet Bajwa, Anmol Cheema, +10 authors, Mohammad A Hossain.
J Clin Med Res, 2019 Apr 03; 11(4). PMID: 30937112    Free PMC article.
Review.
Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors.
Ziqing Chen, Ying Yang, Lisa L Liu, Andreas Lundqvist.
Cancers (Basel), 2019 Jul 26; 11(7). PMID: 31340613    Free PMC article.
Review.
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Sarah Nicol Lauder, Kathryn Smart, +15 authors, Awen Gallimore.
J Immunother Cancer, 2020 Oct 24; 8(2). PMID: 33093155    Free PMC article.
Clinical implication of cellular vaccine in glioma: current advances and future prospects.
Yuanliang Yan, Shuangshuang Zeng, Zhicheng Gong, Zhijie Xu.
J Exp Clin Cancer Res, 2020 Nov 25; 39(1). PMID: 33228738    Free PMC article.
Review.
First line Immunotherapy for Non-Small Cell Lung Cancer.
Nicola J Nasser, Miguel Gorenberg, Abed Agbarya.
Pharmaceuticals (Basel), 2020 Nov 12; 13(11). PMID: 33171686    Free PMC article.
Review.
New emerging targets in cancer immunotherapy: the role of LAG3.
Hannah Christina Puhr, Aysegül Ilhan-Mutlu.
ESMO Open, 2019 Jun 25; 4(2). PMID: 31231559    Free PMC article.
Review.
Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma.
Laila Babar, Juliann E Kosovec, +9 authors, Ali H Zaidi.
Oncotarget, 2019 Jul 31; 10(44). PMID: 31360303    Free PMC article.
CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Stephen T Muth, May Tun Saung, +3 authors, Lei Zheng.
Cancer Lett, 2020 Dec 04; 499. PMID: 33271264    Free PMC article.
Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
Yihang Qi, Li Chen, +3 authors, Jing Wang.
Front Immunol, 2021 Jan 26; 11. PMID: 33488573    Free PMC article.
Review.
Using CRISPR to enhance T cell effector function for therapeutic applications.
Julian J Freen-van Heeren.
Cytokine X, 2021 Feb 20; 3(1). PMID: 33604565    Free PMC article.
Review.
Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.
Sun Min Lim, Min Hee Hong, +8 authors, Hye Ryun Kim.
J Cancer Res Clin Oncol, 2021 Feb 23; 147(9). PMID: 33616718
Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Ahmad Monabati, Pardis Nematollahi, +4 authors, Maral Mokhtari.
Basic Clin Neurosci, 2021 Feb 23; 11(4). PMID: 33613887    Free PMC article.
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Lawrence P Andrews, Ashwin Somasundaram, +14 authors, Dario A A Vignali.
Sci Immunol, 2020 Jul 19; 5(49). PMID: 32680952    Free PMC article.
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Sergio Ayala-Mar, Javier Donoso-Quezada, José González-Valdez.
J Immunol Res, 2021 Feb 26; 2021. PMID: 33628854    Free PMC article.
Review.
High expression of CDCA7 predicts poor prognosis for clear cell renal cell carcinoma and explores its associations with immunity.
Shouyong Liu, Yi Wang, +2 authors, Zengjun Wang.
Cancer Cell Int, 2021 Mar 03; 21(1). PMID: 33648519    Free PMC article.
Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model.
Casey R Ager, Aleksandar Z Obradovic, +4 authors, Charles G Drake.
Cancer Immunol Res, 2021 Feb 28; 9(5). PMID: 33637604    Free PMC article.
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells.
Nadia Bannoud, Tomás Dalotto-Moreno, +5 authors, Diego O Croci.
Front Immunol, 2021 May 25; 12. PMID: 34025660    Free PMC article.
Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples.
Qiang Liu, Yihang Qi, +5 authors, Jing Wang.
Front Immunol, 2021 Jul 17; 12. PMID: 34267742    Free PMC article.
Post-transcriptional control of T-cell cytokine production: Implications for cancer therapy.
Julian J Freen-van Heeren.
Immunology, 2021 Apr 23; 164(1). PMID: 33884612    Free PMC article.
Review.
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).
Andrea De Giglio, Alessandro Di Federico, +2 authors, Francesco Gelsomino.
Curr Oncol Rep, 2021 Aug 29; 23(11). PMID: 34453261    Free PMC article.
Review.
Immunotherapy Treatment for Triple Negative Breast Cancer.
Elizabeth R Berger, Tristen Park, +3 authors, Nita Ahuja.
Pharmaceuticals (Basel), 2021 Aug 29; 14(8). PMID: 34451860    Free PMC article.
Review.
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.
Taofei Zeng, Yuqing Cao, +3 authors, Feng Xu.
J Exp Clin Cancer Res, 2021 Sep 12; 40(1). PMID: 34507594    Free PMC article.
Review.
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma.
Elena-Georgiana Dobre, Carolina Constantin, Marieta Costache, Monica Neagu.
J Pers Med, 2021 Sep 29; 11(9). PMID: 34575678    Free PMC article.
Review.
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
An-Ping Shi, Xi-Yang Tang, +7 authors, Jin-Bo Zhao.
Front Immunol, 2022 Feb 04; 12. PMID: 35111155    Free PMC article.
Review.
Oncology Drug Repurposing for Sepsis Treatment.
Izabela Rumienczyk, Maria Kulecka, +2 authors, Michal Mikula.
Biomedicines, 2022 Apr 24; 10(4). PMID: 35453671    Free PMC article.
Review.
Single-cell atlas of peripheral blood mononuclear cells from pregnant women.
Dongsheng Chen, Wei Wang, +21 authors, Jianmin Niu.
Clin Transl Med, 2022 May 07; 12(5). PMID: 35522918    Free PMC article.